The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the risk of cancers in patients who have used
REGRANEX (becaplermin) to that of patients with similar characteristics and health issues who
have not used REGRANEX (becaplermin). REGRANEX (becaplermin) is topical medication used to
treat non-healing neuropathic foot ulcers in patients with diabetes.